Collectively, our study identified a new potential biomarker, hsa_circ_0072309, for NSCLC and established the hsa_circ_0072309/miR-607/FTO axis in tumorigenesis, which shed light on its application in clinical treatment. The gene discussed is FTO; the disease is non-small cell lung carcinoma.